AAT Antibody (B9): sc-59438

AAT Antibody (B9) is a mouse monoclonal IgG1 antibody that detects α1-antitrypsin (AAT) of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-AAT antibody (B9) is available in a non-conjugated form, providing flexibility for various experimental needs. AAT plays a crucial role in protecting lung tissue from damage caused by Neutrophil Elastase, an enzyme that can lead to pulmonary emphysema, a serious and irreversible lung condition characterized by the loss of elasticity in lung tissue. This 394 amino acid hepatic acute phase protein is primarily synthesized in the liver and is also found in lower concentrations in macrophages. AAT′s structure is particularly important as a highly polymorphic glycosylated serum protein, exhibiting distinct isoelectric-focusing patterns for various genetic variants. The gene encoding AAT is located on human chromosome 14, adjacent to a related serine protease inhibitor gene that encodes corticosteroid-binding globulin. Notably, post-translational modifications, such as the oxidation of the methionine 358 residue in AAT′s active site, can significantly impair elastase inhibition, highlighting the importance of maintaining structural integrity for protective function. AAT deficiency is linked to a 20-30 fold increased risk of developing early-onset pulmonary emphysema, underscoring AAT′s vital role in lung health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AAT Antibody (B9) References:

1. Differential regulation of gene activity and chromatin structure within the human serpin gene cluster at 14q32.1 in macrophage microcell hybrids.  |  Rollini, P. and Fournier, RE. 2000. Nucleic Acids Res. 28: 1767-77. PMID: 10734196
2. A novel binding site for the native hepatic acute-phase protein alpha1-antitrypsin expressed on the human hepatoma cell line HepG 2 and intestinal cell line Caco 2.  |  Graziadei, I., et al. 2000. Liver. 20: 240-6. PMID: 10902975
3. Alpha1-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer.  |  Hsu, PI., et al. 2007. Clin Cancer Res. 13: 876-83. PMID: 17289880
4. Alpha1-antitrypsin protects beta-cells from apoptosis.  |  Zhang, B., et al. 2007. Diabetes. 56: 1316-23. PMID: 17360983
5. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages.  |  Churg, A., et al. 2007. Am J Respir Cell Mol Biol. 37: 144-51. PMID: 17395890
6. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages.  |  Chan, ED., et al. 2007. Scand J Infect Dis. 39: 690-6. PMID: 17654345
7. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone.  |  Seyama, K., et al. 1991. J Biol Chem. 266: 12627-32. PMID: 1905728
8. Characterization of the molecular basis of the alpha 1-antitrypsin F allele.  |  Okayama, H., et al. 1991. Am J Hum Genet. 48: 1154-8. PMID: 2035534
9. The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions.  |  Janciauskiene, S., et al. 2018. Front Pharmacol. 9: 341. PMID: 29719508
10. Alpha1-antitrypsin deficiency and asthma.  |  Pini, L., et al. 2021. Curr Opin Allergy Clin Immunol. 21: 46-51. PMID: 33284159
11. Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo.  |  Janosz, E., et al. 2021. Gene Ther. 28: 477-493. PMID: 34276045
12. Synthesis in yeast of a functional oxidation-resistant mutant of human alpha-antitrypsin.  |  Rosenberg, S., et al. Nature. 312: 77-80. PMID: 6387509

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-AAT Antibody (B9) has 24 citations in a variety of scientific publications.

Primary antibodies like Anti-AAT Antibody (B9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

AAT Antibody (B9) Specifications

Alternate Product Name: AAT

Product Clone Name: B9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: AAT

Epitope Species: human

Product Reactivity/Detection: AAT

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 24 citations in various scientific publications

Available Conjugates/Forms for AAT Antibody (B9): N/A